We are live on ! Find out more
CATX icon

Perspective Therapeutics

50 hedge funds and large institutions have $22M invested in Perspective Therapeutics in 2023 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 9 increasing their positions, 10 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

160% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 5

24% more capital invested

Capital invested by funds: $17.8M → $22M (+$4.26M)

19% more funds holding

Funds holding: 4250 (+8)

0.18% more ownership

Funds ownership: 1%1.18% (+0.18%)

10% less repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 10

Holders
50
Holders Change
+8
Holders Change %
+19.05%
% of All Funds
0.79%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
13
Increased
9
Reduced
10
Closed
5
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
ECM
51
ExodusPoint Capital Management
New York
-$31K -4,872 Closed
DAS
52
Dynamic Advisor Solutions
Arizona
-$25.5K -4,000 Closed
SFS
53
Sowell Financial Services
Arkansas
-$19K -3,000 Closed
Royal Bank of Canada
54
Royal Bank of Canada
Ontario, Canada
-$15.2K -2,496 -99%
ASN
55
Advisory Services Network
Georgia
-$638 -100 Closed

CATX Hedge Fund Activity: Q2 2023 in Review

50 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Perspective Therapeutics (CATX) for Q2 2023, worth a combined $22M — up 24% from $17.8M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new CATX positions and 5 closed out — a net gain of 8 holders — while 9 added to existing stakes and 10 trimmed.

The largest buyer was Baker Bros. Advisors, opening a new position worth an estimated $1.41M. The largest seller was Taylor & Morgan Wealth Management, cutting an estimated $99.7K.

  • 50 institutional investors held Perspective Therapeutics (CATX) as of Q2 2023, up from 42 in Q1 2023.
  • Funds reported $22M of Perspective Therapeutics stock for Q2 2023, up 24% quarter-over-quarter.
  • 13 funds opened new Perspective Therapeutics positions in Q2 2023 and 5 closed out, a net change of +8 holders.
  • The largest Perspective Therapeutics buyer in Q2 2023 was Baker Bros. Advisors, an estimated $1.41M added.
  • The largest Perspective Therapeutics seller in Q2 2023 was Taylor & Morgan Wealth Management, an estimated $99.7K sold.

Based on aggregated 13F filings for Q2 2023.